Samsung Biologics Co Ltd
KRX:207940
Samsung Biologics Co Ltd
Net Income (Common)
Samsung Biologics Co Ltd
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Samsung Biologics Co Ltd
KRX:207940
|
Net Income (Common)
₩857.7B
|
CAGR 3-Years
53%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
P
|
Peptron Inc
KOSDAQ:087010
|
Net Income (Common)
-₩15.9B
|
CAGR 3-Years
5%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
N/A
|
K
|
Knotus Co Ltd
KOSDAQ:278650
|
Net Income (Common)
-₩164m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
S
|
ST Pharm Co Ltd
KOSDAQ:237690
|
Net Income (Common)
₩19.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
F
|
FutureChem Co Ltd
KOSDAQ:220100
|
Net Income (Common)
-₩6.7B
|
CAGR 3-Years
34%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
L
|
LegoChem Biosciences Inc
KOSDAQ:141080
|
Net Income (Common)
-₩73.7B
|
CAGR 3-Years
-119%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-29%
|
See Also
What is Samsung Biologics Co Ltd's Net Income (Common)?
Net Income (Common)
857.7B
KRW
Based on the financial report for Dec 31, 2023, Samsung Biologics Co Ltd's Net Income (Common) amounts to 857.7B KRW.
What is Samsung Biologics Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
31%
Over the last year, the Net Income (Common) growth was 7%. The average annual Net Income (Common) growth rates for Samsung Biologics Co Ltd have been 53% over the past three years , 31% over the past five years .